Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab

Cindy X. Cai(Johns Hopkins University), Patrick Ryan(Johnson & Johnson (United States)), Evan Minty(University of Calgary), Michael E. Matheny(Department of Veterans Affairs), Anthony G. Sena(Erasmus MC), Clair Blacketer(Erasmus MC), Anna Ostropolets(Columbia University), Paul Nagy(Johns Hopkins University), Kenar D. Jhaveri(Hofstra University), Diep Tran(Johns Hopkins University), Thomas Falconer(Columbia University), Jia Hwei Ng(Donald & Barbara Zucker School of Medicine at Hofstra/Northwell), Priya Desai(Stanford Health Care), Jenna Reps(Janssen (United States)), Michael V. Boland(Massachusetts Eye and Ear Infirmary), Mary G. Bowring(Johns Hopkins University), Scott L. DuVall(University of Utah), Kerry Goetz(National Institutes of Health), Zachary Gilbert(Southern California Eye Institute), Marc A. Suchard(University of California, Los Angeles), Asieh Golozar(Northeastern University), Michelle R. Hribar(Primary Source), Nathan Hall(Janssen (United States)), Deidra C. Crews(Johns Hopkins University), George Hripcsak(Columbia University), Azza Shoaibi(Office for National Statistics), Akihiko Nishimura(Johns Hopkins University), Brian C. Toy(Aravind Eye Hospital), Joel N. Swerdel(Janssen (United States)), Jody‐Ann McLeggon(Columbia University Irving Medical Center), Linying Zhang(Columbia University), Laurence Lawrence‐Archer(Northeastern University), Erik Westlund(Johns Hopkins University), Edward Lee(Baylor College of Medicine), Scott L. Zeger(Johns Hopkins University), Fan Bu(University of Michigan), Michael B. Cook(University of Oxford)
Ophthalmology Retina
March 21, 2024
Cited by 16


Related Papers